Crinetics Pharmaceuticals Inc.(CRNX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CRNX Crinetics Pharmaceuticals Inc.

盘后交易 02-05 17:51:53 EST

44.79

-2.64

-5.57%

盘后44.79

+0.000.00%

17:34 EST

最高48.00	最低44.48	成交量104.38万
今开47.42	昨收47.43	日振幅7.42%
总市值45.76亿	流通市值41.55亿	总股本1.02亿
成交额4,757万	换手率1.13%	流通股本9,277万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CRNX","market":"US","secType":"STK","nameCN":"Crinetics Pharmaceuticals Inc.","latestPrice":44.79,"timestamp":1770325200000,"preClose":47.43,"halted":0,"volume":1043843,"hourTrading":{"tag":"盘后","latestPrice":44.79,"preClose":44.79,"latestTime":"17:34 EST","volume":17445,"amount":781361.427885,"timestamp":1770330860952,"change":0,"changeRate":0,"amplitude":0.0023},"delay":0,"changeRate":-0.05566097406704618,"floatShares":92774391,"shares":102168300,"eps":-4.540471,"marketStatus":"盘后交易","change":-2.64,"latestTime":"02-05 17:51:53 EST","open":47.42,"high":48,"low":44.48,"amount":47572854.536646,"amplitude":0.074215,"askPrice":45.08,"askSize":19,"bidPrice":36.84,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.540471,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1770339600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1531886400000,"exchange":"NASDAQ","adjPreClose":47.43,"preHourTrading":{"tag":"盘前","latestPrice":47.42,"preClose":47.43,"latestTime":"09:29 EST","volume":452,"amount":21281.090216,"timestamp":1770301799999,"change":-0.01,"changeRate":-0.000211,"amplitude":0.015391},"postHourTrading":{"tag":"盘后","latestPrice":44.79,"preClose":44.79,"latestTime":"17:34 EST","volume":17445,"amount":781361.427885,"timestamp":1770330860952,"change":0,"changeRate":0,"amplitude":0.0023},"volumeRatio":1.090941,"impliedVol":0.5817,"impliedVolPercentile":0.7171},"requestUrl":"/m/hq/s/CRNX","defaultTab":"news","newsList":[{"id":"1113632150","title":"Crinetics启动Atumelnant治疗先天性肾上腺皮质增生症（CAH）的2/3期儿科临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1113632150","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113632150?lang=zh_cn&edition=full","pubTime":"2026-01-23 05:06","pubTimestamp":1769116007,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc. (CRNX) 已正式启动一项针对儿科患者的2/3期临床试验，旨在评估其研究性药物Atumelnant用于治疗先天性肾上腺皮质增生症（CAH）的疗效与安全性。该研究的启动标志着公司在该疾病领域研发进程中的重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","BK4007","BK4139"],"gpt_icon":0},{"id":"1144961515","title":"Crinetics Pharmaceuticals公布2026年1月根据纳斯达克上市规则5635(C)(4)授予的诱导性股权奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=1144961515","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144961515?lang=zh_cn&edition=full","pubTime":"2026-01-13 05:06","pubTimestamp":1768251976,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc.（以下简称\"公司\"）近日披露，已依据纳斯达克市场上市规则第5635(C)(4)条，于2026年1月向新入职员工授予诱导性股权奖励。此类奖励作为行业常规人才引进措施，旨在吸引高端科研人才加入研发团队。根据相关规定，该次授予计划无需经过股东大会批准，符合新兴生物科技企业通过股权激励构建核心竞争力的普遍实践。公司强调，此次股权分配严格遵循合规流程，展现了其持续强化代谢疾病创新疗法研发实力的战略决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CRNX"],"gpt_icon":0},{"id":"1114259514","title":"Crinetics制药公司宣布拟公开发行普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1114259514","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114259514?lang=zh_cn&edition=full","pubTime":"2026-01-06 05:05","pubTimestamp":1767647101,"startTime":"0","endTime":"0","summary":"圣地亚哥，2026年1月5日——专注于内分泌疾病及内分泌相关肿瘤新型疗法发现、开发和商业化的生物制药公司Crinetics Pharmaceuticals, Inc.今日宣布，计划根据市场及其他条件，通过承销商进行公开发行，拟出售价值3.5亿美元的普通股。此外，公司拟授予承销商为期30天的超额配售选择权，可额外购买最多5250万美元的普通股。本次发行所有股份均由Crinetics出售。本次证券发行依据Crinetics向美国证券交易委员会提交并已自动生效的储架注册声明进行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4555","BK4099","03160","BK4585","BK4007","TM","BK4604","BK4588","CRNX"],"gpt_icon":0},{"id":"1112329282","title":"更正：Crinetics Pharmaceuticals第四季度PALSONIFY美国市场净产品收入突破500万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1112329282","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112329282?lang=zh_cn&edition=full","pubTime":"2026-01-05 21:16","pubTimestamp":1767618997,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc.公布最新财务数据，其核心产品PALSONIFY在美国市场第四季度净销售额超过500万美元。这一业绩表现凸显了该药物在目标治疗领域的商业化进展。\n公司此次披露特意澄清了收入统计口径，明确指出相关数字为产品净收入而非季度总收入，同时移除了与IBES预期数据的对比分析。此举旨在更精准地反映产品实际市场表现，为投资者提供清晰的业务进展评估依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CRNX"],"gpt_icon":0},{"id":"1130017232","title":"Crinetics股价盘前攀升2.7% 新药上市推动第四季度营收超500万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1130017232","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130017232?lang=zh_cn&edition=full","pubTime":"2026-01-05 21:08","pubTimestamp":1767618520,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc. (CRNX) 股价在盘前交易中上涨2.7%，此前该公司公布其新近上市的药物在第四季度创造了超过500万美元的营收。这一积极表现凸显了市场对该新药商业潜力的初步认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CRNX"],"gpt_icon":0},{"id":"1133602751","title":"Crinetics Pharmaceuticals将公布Palsonify业务进展及Atumelnant治疗先天性肾上腺皮质增生症二期试验第四队列顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1133602751","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133602751?lang=zh_cn&edition=full","pubTime":"2026-01-05 05:00","pubTimestamp":1767560414,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc. (CRNX) 即将披露其Palsonify项目的战略发展动态，并同步公开Atumelnant针对先天性肾上腺皮质增生症（CAH）开展的二期临床试验中第四患者队列的顶线研究数据。此次更新将涵盖该创新疗法的临床进展与企业商业布局的双重维度，为市场提供关键研发里程碑的最新洞察。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRNX","BK4139"],"gpt_icon":0},{"id":"1124612366","title":"Crinetics Pharmaceuticals公布2025年12月根据纳斯达克上市规则5635(C)(4)授予的激励补助","url":"https://stock-news.laohu8.com/highlight/detail?id=1124612366","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124612366?lang=zh_cn&edition=full","pubTime":"2025-12-11 05:35","pubTimestamp":1765402509,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals公布2025年12月根据纳斯达克上市规则5635(C)(4)授予的激励补助","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CRNX"],"gpt_icon":0},{"id":"1133077077","title":"Crinetics宣布首位患者在1/2期临床试验中接受Crn09682治疗神经内分泌肿瘤及其他表达生长抑素受体2的肿瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1133077077","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133077077?lang=zh_cn&edition=full","pubTime":"2025-12-03 21:06","pubTimestamp":1764767218,"startTime":"0","endTime":"0","summary":"Crinetics宣布首位患者在1/2期临床试验中接受Crn09682治疗神经内分泌肿瘤及其他表达生长抑素受体2的肿瘤。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","BK4007","BK4139"],"gpt_icon":0},{"id":"1120060913","title":"Crinetics公布首位患者在关键的第三阶段Carefndr试验中随机分组，评估Paltusotine在类癌综合征中的效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1120060913","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120060913?lang=zh_cn&edition=full","pubTime":"2025-11-21 05:06","pubTimestamp":1763672778,"startTime":"0","endTime":"0","summary":"Crinetics公布首位患者在关键的第三阶段Carefndr试验中随机分组，评估Paltusotine在类癌综合征中的效果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRNX","BK4007"],"gpt_icon":0},{"id":"1123922613","title":"Crinetics Pharmaceuticals宣布根据纳斯达克上市规则5635(c)(4)进行2025年11月诱导性授予","url":"https://stock-news.laohu8.com/highlight/detail?id=1123922613","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123922613?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:20","pubTimestamp":1763572835,"startTime":"0","endTime":"0","summary":"11月11日 - Crinetics Pharmaceuticals Inc.宣布，根据纳斯达克上市规则5635(c)(4)，进行2025年11月的诱导性授予。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","CRNX"],"gpt_icon":0},{"id":"1112777962","title":"Crinetics Pharmaceuticals 第三季度净收入为-1.30091亿美金","url":"https://stock-news.laohu8.com/highlight/detail?id=1112777962","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112777962?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:02","pubTimestamp":1763571754,"startTime":"0","endTime":"0","summary":"11月6日 - Crinetics Pharmaceuticals 第三季度收入为14.3万美元，而IBES预测为63.72万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","BK4007","BK4139"],"gpt_icon":0},{"id":"2583689670","title":"Crinetics Pharmaceuticals, Inc.盘中异动 早盘大幅上涨5.60%报43.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583689670","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583689670?lang=zh_cn&edition=full","pubTime":"2025-11-15 00:23","pubTimestamp":1763137412,"startTime":"0","endTime":"0","summary":"北京时间2025年11月15日00时23分，Crinetics Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.60%。Crinetics Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.04%。其相关个股中，Cidara Therapeutics, Inc.、Cypherpunk Technologies Inc.、Invivyd, Inc.涨幅较大，Aspire Biopharma Holdings, Inc.、Cypherpunk Technologies Inc.、Salarius Pharmaceuticals, Inc.较为活跃，换手率分别为970.13%、233.10%、136.59%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Cypherpunk Technologies Inc.、Hcw Biologics Inc.，振幅分别为101.46%、89.22%、59.44%。Crinetics Pharmaceuticals, Inc.公司简介：Crinetics Pharmaceuticals Inc 是一家临床阶段的制药公司，专注于罕见内分泌疾病和内分泌相关肿瘤的新疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511150023329504db1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511150023329504db1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","CRNX"],"gpt_icon":0},{"id":"1113269607","title":"Crinetics Pharmaceuticals 发布2025年11月根据纳斯达克上市规则5635(C)(4)的激励性补助","url":"https://stock-news.laohu8.com/highlight/detail?id=1113269607","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113269607?lang=zh_cn&edition=full","pubTime":"2025-11-11 05:29","pubTimestamp":1762810148,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals 发布2025年11月根据纳斯达克上市规则5635(C)(4)的激励性补助","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CRNX"],"gpt_icon":0},{"id":"2581723868","title":"Crinetics Pharmaceuticals, Inc.盘中异动 股价大跌8.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581723868","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581723868?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:32","pubTimestamp":1762525972,"startTime":"0","endTime":"0","summary":"北京时间2025年11月07日22时32分，Crinetics Pharmaceuticals, Inc.股票出现波动，股价快速下挫8.82%。Crinetics Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.44%。其相关个股中，Metavia Inc.、Dare Bioscience, Inc.、Pharming Group Nv涨幅较大，Metavia Inc.、Phio Pharmaceuticals Corp.、Azitra Inc较为活跃，换手率分别为106.13%、17.53%、9.93%，振幅较大的相关个股有Cytomx Therapeutics, Inc.、Neurosense Therapeutics Ltd.、Metavia Inc.，振幅分别为11.69%、9.70%、9.35%。Crinetics Pharmaceuticals, Inc.公司简介：Crinetics Pharmaceuticals Inc 是一家临床阶段的制药公司，专注于罕见内分泌疾病和内分泌相关肿瘤的新疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251107223252a6e8fc4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251107223252a6e8fc4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRNX","BK4007","BK4139"],"gpt_icon":0},{"id":"2570588794","title":"Crinetics飙升26.6%，其肢端肥大症治疗药物获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2570588794","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570588794?lang=zh_cn&edition=full","pubTime":"2025-09-26 22:57","pubTimestamp":1758898625,"startTime":"0","endTime":"0","summary":"制药企业Crinetics Pharmaceuticals(CRNX)早盘飙升26.6%，获得美国FDA对肢端肥大症治疗药物Palsonify的批准。批准基于成功的三期试验，产品计划于10月初上市。这标志着Crinetics在罕见病治疗领域的重要里程碑。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-09-26/doc-infrvwzi6246219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["SINA","BK4139","CRNX","BK4007"],"gpt_icon":0},{"id":"2570620884","title":"美股异动 | Crinetics(CRNX.US)盘初暴涨23% FDA批准其生长激素紊乱治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2570620884","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570620884?lang=zh_cn&edition=full","pubTime":"2025-09-26 21:57","pubTimestamp":1758895078,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，Crinetics(CRNX.US)盘初暴涨23%，创8个月新高，报44.30美元。消息面上，此前FDA批准了其用于治疗肢端肥大症的药物，这是一种导致体内生长激素过多产生的罕见疾病。这种名为Palsonify的药物是一种每日一次的口服治疗药物，公司预计它将在十月初在美国上市。此次批准基于两项三期试验的数据，试验中药物耐受性良好，并带来了快速且一致的生化控制和症状减轻。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350191.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | Crinetics(CRNX.US)盘初暴涨23% FDA批准其生长激素紊乱治疗方案","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK4139","CRNX"],"gpt_icon":0},{"id":"1175363194","title":"Crinetics Pharmaceuticals Inc.宣布FDA批准Palsonify™ (Paltusotine)用于治疗成人肢端肥大症","url":"https://stock-news.laohu8.com/highlight/detail?id=1175363194","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175363194?lang=zh_cn&edition=full","pubTime":"2025-09-26 05:31","pubTimestamp":1758835876,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc.宣布FDA批准Palsonify™ (Paltusotine)用于治疗成人肢端肥大症","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","BK4139","BK4007"],"gpt_icon":0},{"id":"1166893969","title":"Crinetics Pharmaceuticals宣布FDA批准Palsonifytm（帕图索汀）用于治疗成人肢端肥大症","url":"https://stock-news.laohu8.com/highlight/detail?id=1166893969","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166893969?lang=zh_cn&edition=full","pubTime":"2025-09-26 05:31","pubTimestamp":1758835874,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals宣布，美国食品药品监督管理局（FDA）已批准其药物Palsonifytm（帕图索汀）用于治疗成人肢端肥大症患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","BK4007","BK4139"],"gpt_icon":0},{"id":"1154673720","title":"Crinetics Pharmaceuticals Inc.宣布根据纳斯达克上市规则5635(C)(4)进行2025年9月诱导性授予","url":"https://stock-news.laohu8.com/highlight/detail?id=1154673720","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154673720?lang=zh_cn&edition=full","pubTime":"2025-09-11 04:31","pubTimestamp":1757536283,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc.宣布根据纳斯达克上市规则5635(C)(4)进行2025年9月诱导性授予。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRNX","BK4139"],"gpt_icon":0},{"id":"1102123382","title":"Crinetics Pharmaceuticals Inc.获得FDA孤儿药资格认定，Atumelnant用于治疗先天性肾上腺增生症(CAH)","url":"https://stock-news.laohu8.com/highlight/detail?id=1102123382","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102123382?lang=zh_cn&edition=full","pubTime":"2025-08-21 20:47","pubTimestamp":1755780431,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc.获得FDA孤儿药资格认定，Atumelnant用于治疗先天性肾上腺增生症(CAH)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRNX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.crinetics.com","stockEarnings":[{"period":"1week","weight":-0.0758},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.0906},{"period":"6month","weight":0.7665},{"period":"1year","weight":0.174},{"period":"ytd","weight":0.0189}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0022},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.0769},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.0063}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Crinetics Pharmaceuticals, Inc.于2008年11月18日根据特拉华州法律注册成立。该公司是一家临床阶段制药公司，致力于发现，开发和商业化用于治疗罕见内分泌疾病和内分泌相关肿瘤的新药。 内分泌途径的功能是保持体内平衡，并且通常使用通过G蛋白偶联受体或GPCRs起作用的肽激素来调节生理学的许多方面，包括生长，能量，代谢，胃肠功能和应激反应。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.078473},{"month":2,"riseRate":0.5,"avgChangeRate":-0.005721},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.048453},{"month":4,"riseRate":0.571429,"avgChangeRate":0.068827},{"month":5,"riseRate":0.571429,"avgChangeRate":-0.017869},{"month":6,"riseRate":0.571429,"avgChangeRate":-0.001759},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.025463},{"month":8,"riseRate":0.5,"avgChangeRate":0.05546},{"month":9,"riseRate":0.375,"avgChangeRate":0.104829},{"month":10,"riseRate":0.5,"avgChangeRate":0.007484},{"month":11,"riseRate":0.875,"avgChangeRate":0.104868},{"month":12,"riseRate":0.75,"avgChangeRate":0.036899}],"exchange":"NASDAQ","name":"Crinetics Pharmaceuticals Inc.","nameEN":"Crinetics Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Crinetics Pharmaceuticals Inc.(CRNX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Crinetics Pharmaceuticals Inc.(CRNX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Crinetics Pharmaceuticals Inc.,CRNX,Crinetics Pharmaceuticals Inc.股票,Crinetics Pharmaceuticals Inc.股票老虎,Crinetics Pharmaceuticals Inc.股票老虎国际,Crinetics Pharmaceuticals Inc.行情,Crinetics Pharmaceuticals Inc.股票行情,Crinetics Pharmaceuticals Inc.股价,Crinetics Pharmaceuticals Inc.股市,Crinetics Pharmaceuticals Inc.股票价格,Crinetics Pharmaceuticals Inc.股票交易,Crinetics Pharmaceuticals Inc.股票购买,Crinetics Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Crinetics Pharmaceuticals Inc.(CRNX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Crinetics Pharmaceuticals Inc.(CRNX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}